2026年2月6日起, Agomab治疗公司以16美元的价格为其IPO定价, Agomab Therapeutics priced its IPO at $16, with shares trading on Nasdaq under "AGMB" starting Feb. 6, 2026.

Agomab NV治疗公司将其IPO定价为每美国保管股16.00美元,提供1 250万股,在开销前筹集2亿美元。 Agomab Therapeutics NV priced its IPO at $16.00 per American Depositary Share, offering 12.5 million shares to raise $200 million before expenses. 这些股份代表共同股票,将从2026年2月6日起在“AGMB”之下交易Nasdaq,承保人可选择再购买187.5万股。 The shares, representing common stock, will trade on Nasdaq under "AGMB" starting February 6, 2026, with an option for underwriters to buy 1.875 million additional shares. 由J.P.摩根、摩根·斯坦利、利林伙伴公司和范兰肖特·肯彭管理的提议预计将于2月9日终止,但以标准条件为条件。 The offering, managed by J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, is expected to close on February 9, contingent on standard conditions. 该公司的重点是治疗慢性纤维化疾病,强调这项提议仅在美国提供,并要求在其他地区进行适当登记。 The company, focused on treating chronic fibrotic diseases, emphasized the offering is only in the U.S. and requires proper registration in other regions.